Prostatype Genomics AB (publ) (PGABF)

Market Cap	10.87M +86.4%
Revenue (ttm)	75.19K -82.6%
Net Income	-4.76M
EPS	-0.50
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,000
Average Volume	1,950
Open	0.0850
Previous Close	0.3584
Day's Range	0.0850 - 0.0850
52-Week Range	0.0850 - 0.4000
Beta	n/a
RSI	n/a
Earnings Date	Feb 12, 2026

About Prostatype Genomics AB

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: PGABF

Financial Performance

In 2024, Prostatype Genomics AB's revenue was 1.92 million, a decrease of -48.55% compared to the previous year's 3.73 million. Losses were -41.05 million, -0.93% less than in 2023.

Financial numbers in SEK